Skip to main content
GlaxoSmithkline Pharmaceuticals Ltd. logo

GlaxoSmithkline Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · GLAXO ISIN · INE159A01016 LEI · 3358002TNSC1U2DWNY52 BSE.NS Manufacturing
Open in API
Filings indexed 1,605 across all filing types
Latest filing 2025-10-27 Regulatory Filings
Country IN India
Listing BSE.NS GLAXO

About GlaxoSmithkline Pharmaceuticals Ltd.

https://india-pharma.gsk.com/en-in/home/

GlaxoSmithkline Pharmaceuticals Ltd. is a research-based organization specializing in the development, manufacture, and commercialization of prescription medicines and vaccines. The company’s portfolio spans multiple therapeutic areas, including anti-infectives, dermatology, gynecology, oncology, and respiratory health. Key products include Augmentin, Calpol, Ceftum, and Eltroxin. It maintains a significant presence in the vaccines sector, offering protection against diseases such as pneumococcal infection, hepatitis, and varicella. By integrating global research and development expertise, the entity focuses on delivering innovative treatments and improving patient outcomes. Its operations are supported by a robust supply chain and distribution infrastructure designed to provide broad access to essential medical products.

Recent filings

Filing Released Lang Actions
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve Approval of ....
Regulatory Filings Classification · 95% confidence The document is a letter from GlaxoSmithKline Pharmaceuticals Limited addressed to stock exchanges, informing them about an upcoming Board meeting scheduled for November 6, 2025. The purpose of the meeting is to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2025. The document references the regulatory framework (Listing Obligations and Disclosure Requirements Regulations, 2015) and mentions the financial period but does not contain the actual financial results or detailed financial data. The document length is short (1368 characters) and serves as a notification of an upcoming report approval rather than the report itself. According to the "Menu vs Meal" rule, this is an announcement related to a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement about the timing of financial results approval.
2025-10-27 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 100% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September 2025. It is a compliance certificate from the Registrar and Share Transfer Agent confirming dematerialisation and listing of securities. The document is short (2691 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or substantive financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory compliance documents and certifications that do not fit other specific categories.
2025-10-08 English
As per attachment
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September 2025. It is a compliance certificate from the Registrar and Share Transfer Agent confirming dematerialisation of securities and related actions. The document is addressed to stock exchanges and is a regulatory compliance filing rather than a financial report or announcement of financial results. It does not contain financial statements or management discussion but is a formal attestation letter. The document length is short (2691 characters) and it is a certificate type filing. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance certificate and not a financial report or announcement.
2025-10-08 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter from GlaxoSmithKline Pharmaceuticals Limited addressed to stock exchanges informing about the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations 2015. It specifies the dates during which trading of the company's shares is prohibited due to the upcoming approval and declaration of unaudited financial results for the second quarter and half year ended 30th September 2025. The document does not contain any financial data or results itself, nor does it present a report. It is an announcement related to insider trading restrictions ahead of financial results disclosure. Given the short length (1480 characters) and the nature of the content, this is not a financial report but a regulatory announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-09-29 English
As per attachment
Regulatory Filings Classification · 95% confidence The document is a letter from GlaxoSmithKline Pharmaceuticals Limited addressed to stock exchanges informing about the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations 2015. It specifies the dates during which trading of the company's shares is prohibited due to the upcoming approval and declaration of unaudited financial results for the second quarter and half year ended 30th September 2025. The document does not contain any financial data or results itself, nor does it present a report. It is an announcement related to insider trading restrictions ahead of financial results disclosure. Given the short length (1480 characters) and the nature of the content, this is a regulatory announcement related to compliance and trading restrictions, which fits best under Regulatory Filings (RNS).
2025-09-29 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter from GlaxoSmithKline Pharmaceuticals Limited addressed to stock exchanges regarding the "100 days Campaign - Saksham Niveshak" by the Investor Education and Protection Fund Authority (IEPFA). It includes information about unclaimed dividends, reminder letters to shareholders, and instructions for claiming dividends or shares transferred to IEPF. The document is an announcement or intimation related to shareholder information and regulatory compliance, not a financial report or detailed filing. It is relatively short (2644 characters) and does not contain financial statements or detailed analysis. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require substantive financial data. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement related to shareholder communication and compliance with IEPFA requirements.
2025-09-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.